Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 108 clinical trials
Featured trial
Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis

www.MyelofibrosisResearch.com Myelofibrosis (MF) is a bone marrow illness that affects blood-forming tissues in the

  • 835 views
  • 10 Aug, 2022
  • 226 locations
Featured trial
A Phase 1/2 Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders

ruxolitinib in participants with MF who are transfusion-dependent or presenting with symptomatic anemia. This study will consist of 2 parts: dose escalation and expansion.

anemia
  • 12 views
  • 16 Sep, 2022
  • 20 locations
Featured trial
A Randomized, Double-Blind, Placebo-Controlled Study of the PI3Kδ Inhibitor Parsaclisib Plus Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib

The purpose of the study is to compare the efficacy and safety of parsaclisib when combined with ruxolitinb versus placebo combined with ruxolitinib in participants with myelofibrosis who have suboptimal response while receiving ruxolitinib monotherapy.

  • 6 views
  • 19 Sep, 2022
  • 153 locations
Featured trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3Kδ Inhibitor Parsaclisib and Ruxolitinib in Participants With Myelofibrosis

The purpose of the study is to compare the efficacy of parsaclisib when combined with ruxolitinb versus placebo combined with ruxolitinib in participants with myelofibrosis.

  • 13 views
  • 20 Sep, 2022
  • 129 locations
Featured trial
A Prospective, Observational, US-based Study Assessing Outcomes, Adverse Events, Treatment Patterns, and Quality of Life in Patients Diagnosed With Mycosis Fungoides Cutaneous T-cell Lymphoma and Treated With Valchlor®

A Prospective, Observational, US-based Study Assessing Outcomes, Adverse Events, Treatment Patterns, and Quality of Life in Patients Diagnosed With Mycosis Fungoides Cutaneous T-cell Lymphoma and

  • 607 views
  • 23 Nov, 2020
  • 1 location
Featured trial
A Phase 1/2 Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders

combination with ruxolitinib in participants with MF who are transfusion-dependent or presenting with symptomatic anemia. INCB000928 tablets will be administered orally at a starting dose of 50 mg QD in

anemia
  • 81 views
  • 10 May, 2022
  • 2 locations
Featured trial
Myelofibrosis

Myelofibrosis

  • 574 views
  • 08 Nov, 2020
  • 1 location
Outcomes of MF Patients Exposure to Ruxolitinib During Transplantation

Increasing experience of Ruxolitinib pre-allo SCT and data concerning Ruxolitinib during transplantation Diagnosis MF(includ Post-ET,Post-PV,PMF,MDS/MPN with MF) With at

  • 0 views
  • 05 May, 2022
  • 1 location
Multifamily Guided Self-Help Family-Based Treatment (MF-GSH-FBT) (MF-GSH-FBT)

This is a study testing whether an online Multifamily Guided Self-Help Family Based Treatment (FBT) for Anorexia Nervosa in adolescents aged 12 to 17 is acceptable and useful to families. This online Multifamily Guided Self-Help version of FBT consists of 12 weekly 60-minute telemedicine groups made up of parents from …

  • 0 views
  • 26 Jul, 2022
  • 1 location
Phase 1/2a Open-Label, Dose-Escalation, Multicenter, FIH, Consecutive-Cohort, Clinical Trial of BI-1808, a Monoclonal Antibody to TNFR 2 as a Single Agent and in Combination With Pembrolizumab (MK-3475) in Subjects With Advanced Malignancies (Keynote-D20)

iRECIST can be applied for efficacy assessment) and subjects with cutaneous T-cell lymphoma (CTCL), specifically Sézary Syndrome (SS) and mycosis fungoides (MF). The study will consist of 2 phases

  • 38 views
  • 19 Sep, 2022
  • 5 locations